Investment Rating - The report maintains a "Positive" outlook on the cosmetics and medical beauty industry, suggesting a focus on pre-festival promotions as a key opportunity for growth [3][10]. Core Insights - The cosmetics and medical beauty sector has underperformed the market recently, with the Shenwan Beauty Care Index declining by 3.8% from January 23 to January 30, 2026, which is worse than the overall market performance [4][5]. - Recent earnings forecasts from companies like Shanghai Jahwa, Ruya Chen, and Huaxi Biological indicate a recovery in profitability, highlighting the sector's high growth potential [10][11]. - The upcoming Spring Festival is expected to drive significant promotional activities, particularly on platforms like Tmall and Douyin, which could enhance sales for domestic brands [10][11]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector has shown a decline, with the Shenwan Cosmetics Index down 3.6% and the Shenwan Personal Care Index down 4.6%, both underperforming the Shenwan A Index [4][5]. - The top-performing stocks in the sector include Qingdao Kingway (+7.2%) and Beijia Clean (+0.1%), while the worst performers include Lafang Jiahua (-18.7%) and Shanghai Jahwa (-10.9%) [6]. Earnings Forecasts - Companies like Ruya Chen expect a net profit of 176 to 200 million yuan for 2025, representing a year-on-year increase of 66.61% to 89.33% [4]. - Shanghai Jahwa anticipates a turnaround with a projected net profit of 240 to 290 million yuan for 2025, while Huaxi Biological expects a net profit of 270 to 320 million yuan, reflecting a growth of 54.93% to 83.63% [4][10]. Market Trends - The retail sales of cosmetics in 2025 are projected to grow by 5.1%, with a notable increase in Q4 driven by promotional events like Double Eleven [11][19]. - The report highlights the strong performance of domestic brands, with significant growth in online sales channels, particularly on Douyin [12][29]. Investment Recommendations - Key recommendations include focusing on brands with strong growth in GMV such as Mao Ge Ping, Shangmei Co., and Shanghai Jahwa, as well as companies in the medical beauty sector like Aimeike and Langzi Co. [14][30]. - The report also suggests monitoring e-commerce operations and self-owned brands like Ruya Chen and Qingmu Technology for potential high growth [14][30].

Investment Rating - The report rates the cosmetics and medical beauty industry as "Overweight" for 2025, indicating an expectation for the industry to outperform the overall market [2][11]. Core Insights - The demand side of the cosmetics and medical beauty sector is expected to accelerate, with retail sales of cosmetics projected to reach 465.3 billion yuan in 2025, a year-on-year growth of 5.1%, surpassing the overall retail growth by 1.4 percentage points [3]. - The performance of Hong Kong-listed beauty companies is strong, with significant growth in GMV (Gross Merchandise Volume) through platforms like Douyin, particularly during promotional events like Double Eleven [3]. - The A-share market shows a mixed performance, with companies like Ruoyuchen and Shanghai Jahwa experiencing substantial improvements in their earnings [3]. - The e-commerce operation sector is rebounding, with companies like Ruoyuchen and Yiwang Yichuang expected to see profit growth exceeding 50% in 2025 [3]. - The medical beauty segment is anticipated to face slight fatigue due to macroeconomic factors, but new product launches are expected to stimulate consumer interest in 2026 [3]. Summary by Sections Cosmetics Sector - Retail sales of cosmetics are projected to grow by 5.1% in 2025, with Q4 growth reaching 9.9% [3]. - Key companies such as Shiseido and Lin Qingxuan are expected to see significant GMV growth, with Lin Qingxuan projected to achieve triple-digit growth [3]. - Investment recommendations include companies with strong channel and brand matrices like Maogeping, Shiseido, and Lin Qingxuan, as well as those with improving earnings like Porlaia and Marubi [3]. Medical Beauty Sector - The medical beauty sector is expected to be impacted by macroeconomic conditions, with companies like Aimeike facing challenges [3]. - Recommendations focus on companies with strong R&D capabilities and broad product pipelines, such as Aimeike and Langzi [3]. E-commerce and Operations - The e-commerce operation sector is recovering, with companies like Ruoyuchen and Qingmu Technology expected to see significant profit growth [3]. - The report highlights the importance of self-operated brands and the potential for high growth in this segment [3]. Key Company Valuations - The report provides a valuation table for key companies, indicating a "Buy" rating for several firms including Porlaia, Maogeping, and Shiseido, with projected PE ratios reflecting growth expectations [5].

Investment Rating - The report maintains a positive outlook on the cosmetics and medical beauty sector, highlighting strong performance relative to the market [5][6]. Core Insights - The Tmall Double 11 event showcased strong sales for domestic brands, with significant demand for products from brands like Maogeping and Winona, indicating a robust market response [9][10]. - The cosmetics and medical beauty sector is expected to see continued growth, with Q3 performance meeting expectations and Q4 anticipated to benefit from promotional activities [10][11]. - The report emphasizes the importance of online channels, particularly Tmall and Douyin, in driving sales for domestic brands, which are gaining market share against international competitors [24][26]. Summary by Sections Industry Performance - The cosmetics and medical beauty sector outperformed the market from October 10 to October 17, 2025, with the Shenwan Beauty Care Index declining by 2.5%, which is better than the overall market performance [5][6]. - Key stocks in the sector included Jiaheng Jiahu (+35.0%), Yiyi Co. (+18.6%), and Yanjing Co. (+15.6%), while Maogeping (-7.2%) and Shangmei Co. (-5.4%) lagged [6]. Sales and Market Trends - The report notes that the overall retail sales of cosmetics in China reached 291.5 billion yuan in the first eight months of 2025, with a year-on-year growth of 3.3% [10][16]. - The Tmall Double 11 event attracted over 10 million viewers, with domestic brands experiencing sell-out conditions, indicating strong consumer interest and demand [9][10]. Company Highlights - Han Shu, a brand under Shangmei Co., has shown significant improvement in Tmall channel performance, collaborating with popular influencers to enhance sales [9][10]. - The report highlights the strategic partnership of Han Shu with global ambassador Wang Jiaer, aiming to elevate the brand's international presence and market perception [20][21]. Investment Recommendations - The report recommends focusing on brands with strong online sales growth, such as Maogeping, Shangmei Co., and Shanghai Jahwa, while also monitoring companies like Proya and Marubi for potential performance improvements [12][13]. - In the medical beauty segment, the report suggests investing in companies with strong R&D capabilities and product pipelines, recommending Aimeike as a key player [12][13].

Group 1: Cosmetics and Aesthetic Medicine Sector - The cosmetics retail sales growth in July and August 2025 was 4.5% and 5.1%, outperforming the overall retail market growth of 3.7% and 3.4%, indicating strong demand recovery [1][2] - The Q4 growth is expected to be boosted by the Double Eleven shopping festival and a relatively low base from the previous year, leading to further increases in cosmetics retail sales [1][2] - Domestic brands are leveraging online channels effectively, with notable performances from brands like Mao Geping and others on platforms like Taobao and Douyin [2] Group 2: Company Performance and Trends - Companies like Shuiyang and Beitaini are expected to turn profitable in Q3 2025, showing significant improvement compared to Q3 2024, which was affected by macroeconomic factors [3] - The performance of the aesthetic medicine sector is anticipated to be slightly weak due to macroeconomic influences, with both upstream and downstream segments facing challenges [4] - The mother and baby sector is gaining attention due to government subsidies, with companies like Kid King expected to see substantial profit growth [5] Group 3: Investment Recommendations - Recommended companies in the cosmetics sector include Mao Geping, Shangmei, and Shanghai Jahwa, which have strong growth in GMV [6] - Companies like Aimeike are highlighted for their strong profitability and product pipeline in the aesthetic medicine sector [6] - In the e-commerce and personal care brand space, companies like Ruoyuchen and Shuiyang are suggested for attention [7]